About Shattuck Labs Inc
Shattuck Labs (NASDAQ:STTK) is dedicated to advancing the field of immunotherapy by developing a unique platform that harnesses the power of the immune system to fight disease. The company's innovative approach combines two potent mechanisms to stimulate an immune response against cancers and other diseases, aiming to provide new treatment options for patients. With a focus on transformative projects, Shattuck Labs is actively working on a pipeline of novel agents designed to engage and activate the immune system in a precise, controlled manner. Their objective is to bring groundbreaking therapies to the market, improving outcomes and quality of life for patients enduring various diseases. Shattuck Labs is committed to pushing the boundaries of scientific research to create a future where more diseases are not just treatable, but curable.
Snapshot
Operations
Products and/or services of Shattuck Labs Inc
- Development of SL-172154 (SIRPa-Fc-CD40L) aimed at oncology indications, addressing the dual mechanisms of CD47 immune checkpoint blockade and CD40 co-stimulation for enhanced antitumor activity.
- SL-279252 (PD1-Fc-OX40L) designed for immunotherapy in cancer, leveraging the PD-1 pathway blockade and OX40 agonism to potentially revive and stimulate the immune system against cancer cells.
- Research into novel Agonist Redirected Checkpoint (ARC) platform technology, creating fusion proteins that combine immune checkpoint blockade with costimulatory activation for potential cancer immunotherapy solutions.
- Collaborations with leading pharmaceutical companies to expand the application and leverage of ARC platform in various therapeutic areas, enhancing drug discovery and development processes.
- Commitment to pipeline expansion through strategic partnerships and acquisitions, focusing on innovative therapies that address unmet medical needs in oncology and other diseases.
- Investment in advanced manufacturing processes and facilities to ensure the high-quality production of its biologics, supporting rapid development and large-scale manufacturing capabilities for future products.
Shattuck Labs Inc executive team
- Dr. Taylor H. Schreiber M.D., Ph.D.Co-Founder, CEO & Director
- Mr. Andrew R. Neill M.B.A.Chief Financial Officer
- Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.Chief Medical Officer
- Dr. Abhinav A. Shukla Ph.D.Chief Technical Officer
- Dr. Stephen Stout J.D., Ph.D.General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
- Ms. Casi DeYoungChief Business Officer
- Dr. Thomas Lampkin Pharm.D.Senior Vice President of Regulatory Affairs
- Mr. Suresh de Silva Ph.D.Chief Scientific Officer
- Ms. Kelli Collin M.S.Senior Vice President of Quality